LUCD
Lucid Diagnostics Inc.
$1.00
+0.01 (+1.01%)
At close · Jul 10
Market Cap
$203.07M
Shares
203,066,783
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.71M
+8.3%
FY2025
Net Income
-$58.01M
-27.4%
FY2025
Gross Margin
100%
+117pp
FY2022
Operating Margin
-1054.82%
+4.8pp
FY2025
Diluted EPS
-$1.05
+16.7%
FY2024
Operating Cash Flow
-$46.49M
-5.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $5.13M | $4.71M | $4.35M | $2.43M | $377K | $500K | |
| — | $6.67M | — | — | $100M | $585K | |
| — | — | — | — | $377K | -$85K | |
| — | — | — | — | 100% | -17% | |
| $5.46M | $5.68M | $5.99M | $7.25M | $11.47M | $9.3M | |
| $18.64M | $17.71M | $16.46M | $16.4M | $16.13M | $5.26M | |
| $23.14M | $23.87M | $20.16M | $19.25M | $23.69M | $12.78M | |
| — | — | — | — | $21K | $21K | |
| $421K | $421K | $688K | $2.02M | $1.65M | — | |
| — | $872K | $1.17M | $2.5M | $1.94M | — | |
| $52.4M | — | $50.4M | $50.91M | $56.55M | $27.33M | |
| — | $54.35M | — | — | — | — | |
| -$49.27M | -$49.64M | -$46.05M | -$48.48M | -$56.17M | -$27.42M | |
| — | -1054.82% | -1059.64% | -1996.79% | -14899.47% | -5483.8% | |
| — | -$48.77M | -$44.89M | -$45.98M | -$54.24M | — | |
| $19K | $22K | $26K | $416K | — | — | |
| — | $386K | — | — | — | — | |
| $4.26M | -$8.37M | $523K | -$4.18M | -$659K | — | |
| -$45.01M | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -$28.08M | |
| — | $0 | — | — | — | — | |
| -$45.01M | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -$28.08M | |
| — | -1232.68% | -1047.61% | -2169.11% | -14899.47% | -5615.6% | |
| -$58.18M | -$70.57M | -$53.03M | — | — | — | |
| USD/shares | — | -$0.69 | -$1.05 | -$1.26 | -$1.55 | — |
| USD/shares | — | — | -$1.05 | -$1.26 | — | — |
| shares | — | 101.95M | 50.52M | 41.76M | 36.17M | 18.6M |
| shares | — | — | 50.52M | 41.76M | — | 18.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.38×
EV/EBIT
—
Medical Devices median 21.54×
P/E (TTM)
—
Medical Devices median 26.77×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2022-12-31 |
|---|---|
| EsoGuard Test | $188,000 |